{"text": "Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.", "user_data": {"pmid": "10080213"}}
{"text": "Comparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.", "user_data": {"pmid": "10080213"}}
{"text": "Mean \"C\" was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).", "user_data": {"pmid": "10080213"}}
{"text": "A remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.", "user_data": {"pmid": "10080213"}}
{"text": "Darkening of the peripheral iris stroma was suspected in two patients treated with latanoprost.", "user_data": {"pmid": "10080213"}}
{"text": "Complications during the 5-year follow-up were also statistically similar.", "user_data": {"pmid": "10599663"}}
{"text": "Of 224 patients 213 were included in the analysis of efficacy.", "user_data": {"pmid": "10837379"}}
{"text": "The difference of 2.9 mm Hg (95% CI: 2.3-3.6) was highly significant (p<0.001, ANCOVA).", "user_data": {"pmid": "10837379"}}
{"text": "Both drugs were well tolerated systemically and locally.", "user_data": {"pmid": "10837379"}}
{"text": "Few patients reported a specific adverse event and, with the exception of a slightly higher rate of ocular burning and stinging in the brimonidine group, there were no significant between-group differences.", "user_data": {"pmid": "10877373"}}
{"text": "No significant chronotropic effects on the heart were seen with brimonidine, while small but significant mean decreases in heart rate were seen at months 1 and 4 with timolol.", "user_data": {"pmid": "10877373"}}
{"text": "Mean systolic and diastolic blood pressure remained relatively stable in both groups.", "user_data": {"pmid": "10877373"}}
{"text": "Quality of life remained stable, with no significant between-group differences.", "user_data": {"pmid": "10877373"}}
{"text": "Four patients on latanoprost 0.005% and 35 on pilocarpine 2% did not complete the study (P<0.001).", "user_data": {"pmid": "10901475"}}
{"text": "Two hundred and forty patients were included in the intent-to-treat analysis.", "user_data": {"pmid": "10901475"}}
{"text": "For both treatments the diurnal IOP reduction after 6 months was statistically significant (P<0.001).", "user_data": {"pmid": "10901475"}}
{"text": "The mean difference of -0.8 mmHg (per protocol, PP) and -1.6 mmHg (intend-to-treat, ITT) was statistically significant (P<0.04, PP; P<0.001, ITT) in favor of latanoprost 0.005%.", "user_data": {"pmid": "10901475"}}
{"text": "Two eyes treated with latanoprost showed an iris color change.", "user_data": {"pmid": "10901475"}}
{"text": "Thirty-six patients in the latanoprost group and 106 in the pilocarpine 2% group reported ocular adverse events (P<0.001).", "user_data": {"pmid": "10901475"}}
{"text": "Compared with preoperative status, no statistically significant differences between groups were noted for visual acuity, visual field, lens status, and final anterior chamber depth.", "user_data": {"pmid": "11020403"}}
{"text": "However, the Ahmed implant group had a greater adjunctive medication requirement.", "user_data": {"pmid": "11020403"}}
{"text": "On the last visit, 10 of the trabeculectomy eyes and 19 of the Ahmed implant eyes required at least one topical medication (P =.01).", "user_data": {"pmid": "11020403"}}
{"text": "There was no statistically significant difference in the rate of complications between the two groups.", "user_data": {"pmid": "11020403"}}
{"text": "These differences were not statistically significant.", "user_data": {"pmid": "11124286"}}
{"text": "Survival analysis showed a tendency but no statistically significant difference between treatment groups (P = 0.07).", "user_data": {"pmid": "11148810"}}
{"text": "Study attrition was large.", "user_data": {"pmid": "11148810"}}
{"text": "Eighteen patients in each group had developed glaucomatous field loss when also post-study data were included.", "user_data": {"pmid": "11148810"}}
{"text": "IOP reduction was greater in eyes passing the 10-year visit without field loss (5.7 mmHg), than in those that reached an end-point (2.3 mmHg; P = 0.0002).", "user_data": {"pmid": "11148810"}}
{"text": "The difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.", "user_data": {"pmid": "11158796"}}
{"text": "A >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.", "user_data": {"pmid": "11158796"}}
{"text": "The incidence of adverse events was low and comparable between the groups.", "user_data": {"pmid": "11158796"}}
{"text": "Latanoprost reduced the intraocular pressure 1.09 and 1.58 mm Hg more than timolol plus dorzolamide after 2 weeks and 3 months of treatment, respectively.", "user_data": {"pmid": "11167277"}}
{"text": "These differences were statistically significant (p<0.05) at the end of the study.", "user_data": {"pmid": "11167277"}}
{"text": "Fifty-six patients completed both treatment periods and had intraocular pressure data available for evaluation.", "user_data": {"pmid": "11336940"}}
{"text": "The difference of 1.9 mm Hg between treatments was statistically significant in favor of latanoprost [P =.003, analysis of covariance (ANCOVA)].", "user_data": {"pmid": "11336940"}}
{"text": "Unadjusted analysis of responders using the percentage decrease in intraocular pressure showed that the proportion of responders in the latanoprost-treated group was greater than in the unoprostone-treated group.", "user_data": {"pmid": "11336940"}}
{"text": "Adverse ocular symptoms and findings were mild in both treatment groups.", "user_data": {"pmid": "11336940"}}
{"text": "Eye redness and ocular irritation were the most frequently reported events.", "user_data": {"pmid": "11336940"}}
{"text": "The diurnal intraocular pressure reduction was significant in both groups (P < 0.001).", "user_data": {"pmid": "11558817"}}
{"text": "Drugs administered in both treatment groups were well tolerated.", "user_data": {"pmid": "11558817"}}
{"text": "Mean baseline values (25 mm Hg) for subjects at eligibility (while maintained on timolol) were not significantly different (P <.0001) among the treatment groups.", "user_data": {"pmid": "11730649"}}
{"text": "These changes were significantly (P < or =.0001) different from the vehicle group (-1.3 to -2.8 mm Hg).", "user_data": {"pmid": "11730649"}}
{"text": "The intraocular pressure range on treatment at all visit times over the 6-month treatment period ranged from 17.9 to 19.2 mm Hg for travoprost 0.004% and 18.3 to 20.1 mm Hg for travoprost 0.0015% compared with 22.4 to 24.1 mm Hg for vehicle.", "user_data": {"pmid": "11730649"}}
{"text": "Average hyperemia scores ranged from trace to mild (mean 0.5 on a scale of 0 = none/trace; 1= mild; 2 = moderate; 3 = severe) for all treatment groups.", "user_data": {"pmid": "11730649"}}
{"text": "No iris pigmentation changes were observed in any patient during this study.", "user_data": {"pmid": "11730649"}}
{"text": "There were no clinically or statistically significant changes from baseline in visual acuity, ocular cells and flare, fundus parameter, cup-to-disk ratio and visual field between the treatment groups.", "user_data": {"pmid": "11730649"}}
{"text": "There were no serious adverse events reported for any treatment group.", "user_data": {"pmid": "11730649"}}
{"text": "Of the 379 randomized patients, 375 were included in the intent-to-treat analysis.", "user_data": {"pmid": "11912355"}}
{"text": "This 1.9 mm Hg difference in intraocular-pressure reduction was significantly in favor of latanoprost (P < 0.001).", "user_data": {"pmid": "11912355"}}
{"text": "Ocular allergy (P < 0.001) and systemic side effects (P = 0.005) were reported significantly less frequently by latanoprost-treated patients compared with brimonidine-treated patients.", "user_data": {"pmid": "11912355"}}
{"text": "The mean (SD) preoperative intraocular pressure was 27.1 (7.1) mm Hg for all patients enrolled.", "user_data": {"pmid": "12169965"}}
{"text": "The number of postoperative complications was lower in the viscocanalostomy group than in the trabeculectomy group.", "user_data": {"pmid": "12169965"}}
{"text": "Of the 115 eyes, 57 received 5-FU while 58 received MMC.", "user_data": {"pmid": "12383808"}}
{"text": "The most common complications in each group were persistent choroidal effusions and bleb leak.", "user_data": {"pmid": "12383808"}}
{"text": "No serious adverse event related to either medication was reported.", "user_data": {"pmid": "12470755"}}
{"text": "Two hundred and fifty-five patients completed the study, which ended in 1998, with a range of follow-up of 2-6 years.", "user_data": {"pmid": "12644943"}}
{"text": "The intent-to-treat analysis demonstrated no evidence of any difference in conversion rates between the betaxolol and placebo groups after 3 years.", "user_data": {"pmid": "12644943"}}
{"text": "Visual field survival analysis demonstrated no significant difference between the betaxolol and placebo groups.", "user_data": {"pmid": "12644943"}}
{"text": "The betaxolol-treated group had significantly lower post-treatment IOP values.", "user_data": {"pmid": "12644943"}}
{"text": "Converters had significantly higher pre- and post-treatment IOP values than non-converters.", "user_data": {"pmid": "12644943"}}
{"text": "Efficacy-of the 151 patients included in the study, 149 were evaluated (two patients were lost to follow-up after day 0): 74 in the alginate group and 75 in the standard group.", "user_data": {"pmid": "12660585"}}
{"text": "Both treatment groups were comparable at day 0 except for sex, diastolic blood pressure, and IOP in the fellow eye.", "user_data": {"pmid": "12660585"}}
{"text": "At 11.00 hours (presumed peak), mean reductions were 6.70+/-2.81 and 6.55+/-3.35 mmHg, respectively.", "user_data": {"pmid": "12660585"}}
{"text": "At each evaluation time, the two unilateral t tests were highly significant (p<0.005), confirming the equivalence of both treatments.", "user_data": {"pmid": "12660585"}}
{"text": "Conclusions were not modified taking into account sex and diastolic blood pressure.", "user_data": {"pmid": "12660585"}}
{"text": "Safety- Slight decreases in heart rate and blood pressure means were observed in both groups at follow-up visits with no significant difference between groups.", "user_data": {"pmid": "12660585"}}
{"text": "Transient discomfort (mainly stinging or burning sensation) was reported by approximately 4% - 6% of patients in each treatment group at each visit.", "user_data": {"pmid": "12660585"}}
{"text": "Among the 17 reported adverse events, three were assessed as drug-related: one vertigo, one superficial punctate keratitis in the alginate group and one decrease in blood pressure in the standard group.", "user_data": {"pmid": "12660585"}}
{"text": "No serious adverse events were reported.", "user_data": {"pmid": "12660585"}}
{"text": "Complications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases.", "user_data": {"pmid": "12750084"}}
{"text": "Complications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.", "user_data": {"pmid": "12750084"}}
{"text": "No patient required reoperation.", "user_data": {"pmid": "12750084"}}
{"text": "Two eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.", "user_data": {"pmid": "12750084"}}
{"text": "Both drugs showed sustained ocular hypotensive efficacy in the study period.", "user_data": {"pmid": "12908569"}}
{"text": "The IOP readings after treatment were significantly lower than their baseline levels in both groups at all visits (p < 0.001).", "user_data": {"pmid": "12908569"}}
{"text": "No significant between-group differences were seen at peak or trough at all visits.", "user_data": {"pmid": "12908569"}}
{"text": "No significant changes in visual acuity, biomicroscopy or ophthalmoscopy were observed in both groups.", "user_data": {"pmid": "12908569"}}
{"text": "Mean systolic and diastolic blood pressure remained relatively stable in both groups except in week 2 (p = 0.016) when brimonidine had lower systolic blood pressure.", "user_data": {"pmid": "12908569"}}
{"text": "However, brimonidine showed no significant difference in week 4 from baseline.", "user_data": {"pmid": "12908569"}}
{"text": "The mean heart rate in the brimonidine group was relatively unchanged over the study period.", "user_data": {"pmid": "12908569"}}
{"text": "Patients receiving timolol experienced statistically significant mean heart rate decreases from baseline (p = 0.020) in week 4.", "user_data": {"pmid": "12908569"}}
{"text": "Bimatoprost provided significantly greater IOP lowering compared with combined timolol and dorzolamide.", "user_data": {"pmid": "14644719"}}
{"text": "At the last follow-up, patients had better diurnal IOP control with bimatoprost than combined timolol and dorzolamide.", "user_data": {"pmid": "14644719"}}
{"text": "At 8 AM at the 3-month visit, the percentages of patients achieving IOPs of <or =13 mmHg, < or =14 mmHg, < or =15 mmHg, or < or =16 mmHg were more than twice as high for bimatoprost than for combined timolol and dorzolamide (all P< or =0.008).", "user_data": {"pmid": "14644719"}}
{"text": "Taste perversion, ocular burning, and stinging with instillation were more common with combined timolol and dorzolamide, whereas conjunctival hyperemia was more common with bimatoprost.", "user_data": {"pmid": "14644719"}}
{"text": "Over a follow-up period of 1 year, no statistically significant differences were detected between the Baerveldt-350 implant versus Ahmed valve for IOP control (12.1 +/- 5.3 mm Hg vs. 13.6 +/- 5.6 mm Hg respectively, at a power of 90% to detect a difference of 3.2 mm Hg between the two groups and P = 0.05), surgical success rate (65.6% vs. 65.6% respectively, complete and qualified combined), postoperative hypotony rate (37.5% vs. 34.4% respectively), and visual acuity changes of more than 1 line in Snellen visual acuity (43.3% vs. 29.0% respectively).", "user_data": {"pmid": "14704542"}}
{"text": "The difference between treatments in mean IOP change at 3 months was -0.04 mmHg [95% confidence interval (CI) -0.85, 0.77] in Study 1, and -0.57 mmHg (95% CI -1.31, 0.16) in Study 2.", "user_data": {"pmid": "14982045"}}
{"text": "The probability that the true difference lay between -1.5 and 1.5 mmHg, the predefined bounds for equivalence, was >0.950 in both studies.", "user_data": {"pmid": "14982045"}}
{"text": "Both treatments were well tolerated over 3 months, although ocular stinging occurred more frequently with the dorzolamide/timolol combination.", "user_data": {"pmid": "14982045"}}
{"text": "Percentage of IOP reduction or the magnitude of IOP reduction showed no intergroup differences either at any time point (13-15%).", "user_data": {"pmid": "15037889"}}
{"text": "The estimated rate of change in MD showed no significant difference from zero in both groups, and there were no statistical intergroup differences.", "user_data": {"pmid": "15037889"}}
{"text": "No changes in the optic nerve head topography in the vertical cup-to-disc ratio and rim area measured by image-analysis techniques were observed in either group.", "user_data": {"pmid": "15037889"}}
{"text": "There were no patients who dropped out due to the side effects of treatment regimens.", "user_data": {"pmid": "15037889"}}
{"text": "There were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).", "user_data": {"pmid": "15177955"}}
{"text": "After 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.", "user_data": {"pmid": "15177955"}}
{"text": "Mean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.", "user_data": {"pmid": "15177955"}}
{"text": "There was no significant difference between the incidences of postoperative complications in both groups.", "user_data": {"pmid": "15177955"}}
{"text": "A total of 229 patients were randomized (latanoprost, n = 112; dorzolamide/timolol, n = 117).", "user_data": {"pmid": "15220019"}}
{"text": "Mean baseline diurnal IOP values were similar between the 2 groups.", "user_data": {"pmid": "15220019"}}
{"text": "Mean IOP values were similar at all time points except at 5:00 pm, when levels were significantly lower in latanoprost-treated patients (P = 0.025).", "user_data": {"pmid": "15220019"}}
{"text": "After the water-drinking test, the increase in IOP values was similar between groups at baseline but lower in latanoprost-treated patients at week 8 (adjusted difference, 1.08 mm Hg; P = 0.012).", "user_data": {"pmid": "15220019"}}
{"text": "Fewer patients treated with latanoprost reported ocular or systemic AEs (P = 0.025 and P < 0.001, respectively).", "user_data": {"pmid": "15220019"}}
{"text": "A decrease in IOP of 56.6% and 65.9% had been achieved.", "user_data": {"pmid": "15234141"}}
{"text": "Postoperative hypotony and cataract formation occurred more frequently in the trabeculectomy group than in the viscocanalostomy group (P=.002).", "user_data": {"pmid": "15474813"}}
{"text": "A total of 350 patients were enrolled.", "user_data": {"pmid": "15598478"}}
{"text": "Baseline demographic and clinical characteristics were similar between groups.", "user_data": {"pmid": "15598478"}}
{"text": "Both treatments were well tolerated.", "user_data": {"pmid": "15598478"}}
{"text": "Baseline mean diurnal IOP levels were similar between groups.", "user_data": {"pmid": "15741820"}}
{"text": "The mean difference in diurnal IOP reduction was 2.5 +/- 0.3 mm Hg (95% CI: 1.9, 3.2; P < 0.001).", "user_data": {"pmid": "15741820"}}
{"text": "Five times more patients receiving brimonidine than latanoprost were withdrawn from the study due to adverse events.", "user_data": {"pmid": "15741820"}}
{"text": "A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group.", "user_data": {"pmid": "17083910"}}
{"text": "Differences in IOP between the bimatoprost and timolol-dorzolamide groups were statistically insignificant at all study visits (p > 0.05).", "user_data": {"pmid": "17244215"}}
{"text": "The difference was not statistically significant (p = 0.48).", "user_data": {"pmid": "17244215"}}
{"text": "Mean follow-up was 40 months (SD 15), with a range from 6 to 60 months.", "user_data": {"pmid": "17293790"}}
{"text": "IOP was lower in the trab group with differences in IOP being statistically significant at month 12 (P=<0.001), 24 (P=<0.001), 30 (P=0.030), 36 (P=<0.001), and 48 (P=0.018).", "user_data": {"pmid": "17293790"}}
{"text": "The trabeculectomy group required less postoperative topical IOP-lowering medication (P=0.011).", "user_data": {"pmid": "17293790"}}
{"text": "There was no significant difference in the mean IOP between the groups at any time.", "user_data": {"pmid": "17397924"}}
{"text": "Intraocular pressure was significantly reduced during the entire follow-up period in both groups.", "user_data": {"pmid": "17601060"}}
{"text": "In the long-acting drug group, the reduction of intraocular pressure was--3.5 +/- 0.2,--4.3 +/- 0.2 and--4.6 +/- 0.3 mmHg at 2, 4, and 8 weeks, respectively (paired t test).", "user_data": {"pmid": "17601060"}}
{"text": "In the currently-prescribed drug group, the reduction of intraocular pressure was--4.1 +/- 0.2,--4.4 +/- 0.3 and--4.6 +/- 0.2 mmHg at 2, 4, and 8 weeks(paired t test).", "user_data": {"pmid": "17601060"}}
{"text": "The safety profile was similar in both groups, and the tolerance for the long-acting eye drops was as good as for the currently-prescribed eye drops.", "user_data": {"pmid": "17601060"}}
{"text": "Visual acuity was similar for both groups at 3 months after surgery.", "user_data": {"pmid": "17825417"}}
{"text": "There were no significant differences in the need for digital pressure, postoperative bleb needling with 5-fluorouracil, or number of postoperative visits.", "user_data": {"pmid": "17825417"}}
{"text": "There were 2 major complications in each group during follow-up.", "user_data": {"pmid": "17825417"}}
{"text": "Early leaks of the conjunctival wound closure occurred in 6 eyes in the 1-site group and in 0 eyes in the 2-site group (P = 0.03).", "user_data": {"pmid": "17825417"}}
{"text": "Operating time (in minutes) was less in the 1-site surgery group (P<0.0001).", "user_data": {"pmid": "17825417"}}
{"text": "Day one postoperative IOP was higher in the 2-site group (P = 0.0.01).", "user_data": {"pmid": "17825417"}}
{"text": "The 2 groups were similar with regards to age, gender, race, neovascular glaucoma diagnosis, number of prior ocular surgeries, preoperative IOP, and number of preoperative glaucoma medications.", "user_data": {"pmid": "18164068"}}
{"text": "Male gender, African descent, neovascular glaucoma, and Ahmed implantation were found to be significant predictors of failure.", "user_data": {"pmid": "18164068"}}
{"text": "Two methods for avoiding hypotony after Baerveldt 250-mm(2) implantation had similar outcomes.", "user_data": {"pmid": "18164068"}}
{"text": "A total of 120 patients were randomized to 2 equal treatment groups.", "user_data": {"pmid": "18327364"}}
{"text": "The mean baseline IOP values were similar between the 2 groups.", "user_data": {"pmid": "18327364"}}
{"text": "The 2 therapies were similarly effective.", "user_data": {"pmid": "18327364"}}
{"text": "Adjunctive use of brimonidine purite provided greater IOP lowering than brinzolamide at 10 a.m. (p < 0.001) and 4 p.m. (p = 0.050) and equivalent IOP lowering to brinzolamide at 8 a.m. (p = 0.716).", "user_data": {"pmid": "18402717"}}
{"text": "Blurred vision at Month 1 and bitter taste at Months 1 and 3 were more common upon instillation of brinzolamide eye drops.", "user_data": {"pmid": "18402717"}}
{"text": "Two patients in group A required reformation of anterior chamber.", "user_data": {"pmid": "18603947"}}
{"text": "Other surgical complications in the two groups were similar.", "user_data": {"pmid": "18603947"}}
{"text": "Both the groups had a significant drop in IOP following surgery.", "user_data": {"pmid": "18603947"}}
{"text": "There was a significant drop in IOP following removal of sutures (15.19 +/- 6.15 mmHg to 13.19 +/- 6.13 mmHg; p=006) in group B.", "user_data": {"pmid": "18603947"}}
{"text": "The mean IOP in the first period when all patients were dosed in the evening was assessed 12\u2009h after dosing at 09:00 and it was similar in the two treatment groups (mean\u2009\u00b1\u2009standard deviation: 17.9\u2009\u00b1\u20092.7\u2009mmHg for travoprost versus 17.7\u2009\u00b1\u20092.5\u2009mmHg for latanoprost, p\u2009=\u20090.812).", "user_data": {"pmid": "18826749"}}
{"text": "In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower (\u2009p\u2009<\u20090.001) on travoprost (16.9\u2009\u00b1\u20093.1\u2009mmHg) compared to latanoprost (18.6\u2009\u00b1\u20093.3\u2009mmHg).", "user_data": {"pmid": "18826749"}}
{"text": "In the exit survey, 51% of patients preferred a.m.-dosing.", "user_data": {"pmid": "18826749"}}
{"text": "A total of 210 patients were randomized (brimonidine/timolol, n=111; dorzolamide/timolol, n=99).", "user_data": {"pmid": "19092465"}}
{"text": "Mean diurnal IOP reduction after 8 weeks were 7.02+/-3.06 mm Hg and 6.91+/-3.67 mm Hg, respectively (P=0.811).", "user_data": {"pmid": "19092465"}}
{"text": "The adjusted difference between groups (analysis of covariance) at week 8 was not statistically significant (P=0.847).", "user_data": {"pmid": "19092465"}}
{"text": "After 8 weeks of treatment, mean WDT peaks were 20.94+/-3.76 mm Hg (P<0.001) and 20.98+/-4.19 (P<0.001), respectively.", "user_data": {"pmid": "19092465"}}
{"text": "The adjusted difference between groups (analysis of covariance) was not statistically significant (P=0.469).", "user_data": {"pmid": "19092465"}}
{"text": "No statistical difference in terms of adverse events was found between groups.", "user_data": {"pmid": "19092465"}}
{"text": "Both treatments were effective in reducing the IOP from baseline.", "user_data": {"pmid": "19123151"}}
{"text": "Twenty-seven CACG eyes were randomized into group 1, and 24 CACG eyes were randomized into group 2.", "user_data": {"pmid": "19243831"}}
{"text": "Combined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs. 17.0 mmHg, P = 0.01), 15 months (13.2 vs. 15.4 mmHg, P = 0.02), and 18 months (13.6 vs. 15.9 mmHg, P = 0.01).", "user_data": {"pmid": "19243831"}}
{"text": "Combined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.", "user_data": {"pmid": "19243831"}}
{"text": "Combined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.", "user_data": {"pmid": "19243831"}}
{"text": "Fifty-four subjects (80 eyes) completed the study.", "user_data": {"pmid": "19336424"}}
{"text": "There were 78 patients (80 eyes) with primary open-angle, pseudoexfoliative, or pigmentary glaucoma enrolled in the study.", "user_data": {"pmid": "19337705"}}
{"text": "The respective proportions of patients achieving an IOP >4 mmHg and <or=15 mmHg were 76.9% and 50.0% (P=0.0193).", "user_data": {"pmid": "19337705"}}
{"text": "There was a similar level of postoperative interventions and complications for each group.", "user_data": {"pmid": "19337705"}}
{"text": "There were no significant differences between groups in either IOP or the number of glaucoma medications throughout the 3-year follow-up.", "user_data": {"pmid": "19383599"}}
{"text": "The incidences of postoperative complications were similar between groups (p = 0.232).", "user_data": {"pmid": "19383599"}}
{"text": "Both treatments resulted in significant reductions in mean intervisit IOP range during 26 weeks.", "user_data": {"pmid": "19427617"}}
{"text": "Pretreatment, comparable proportions of patients treated with latanoprost and timolol had high intervisit IOP ranges (22% [70/313] and 23% [72/318], respectively; P = .934).", "user_data": {"pmid": "19427617"}}
{"text": "Significant risk factors for high posttreatment intervisit range (multivariate logistic regression) were high pretreatment intervisit IOP range, treatment with timolol, Black race, longer time since diagnosis, and higher mean pretreatment IOP.", "user_data": {"pmid": "19427617"}}
{"text": "There were no statistically significant between-group differences in patient demographics.", "user_data": {"pmid": "19476406"}}
{"text": "Most patients were Caucasian, and the mean age was 68 years.", "user_data": {"pmid": "19476406"}}
{"text": "There were also no statistically significant differences between treatment groups in baseline IOP.", "user_data": {"pmid": "19476406"}}
{"text": "Patients on brimonidine-timolol reported less burning (p < 0.001), stinging (p < 0.001), and unusual taste (p < 0.001) than patients on dorzolamide-timolol.", "user_data": {"pmid": "19476406"}}
{"text": "Also, the change in mean IOP values was significantly higher in the latanoprost/timolol group at 10:00 am (P = 0.013) and 12:00 pm (P = 0.01), but not at 8:00 am (P = ns).", "user_data": {"pmid": "19860553"}}
{"text": "During the water-drinking test, there was no significant difference in IOP increase (absolute and percentage) between groups; however, there was a significant decrease in mean heart rate in the latanoprost/timolol group.", "user_data": {"pmid": "19860553"}}
{"text": "Finally, no significant changes in blood pressure and lung spirometry were observed in either groups.", "user_data": {"pmid": "19860553"}}
{"text": "Three hundred and twenty-six patients received >or = 1 dose of latanoprost (n = 162) or non-PGs (n = 164).", "user_data": {"pmid": "19900212"}}
{"text": "Decreases in mean diurnal IOP from baseline were significantly greater for latanoprost than for non-PGs at months 6 and 12 (p < 0.01).", "user_data": {"pmid": "19900212"}}
{"text": "No serious adverse events were judged to be treatment-related.", "user_data": {"pmid": "19900212"}}
{"text": "Mean total 36-month direct costs were similar in patients initiated with latanoprost and non-PGs.", "user_data": {"pmid": "19900212"}}
{"text": "Thirty-nine patients completed the study (19 in the study group, 20 in the control group).", "user_data": {"pmid": "20092592"}}
{"text": "There was no statistically significant difference in the mean values of Schirmer's tear test 1 and the level of conjunctival hyperaemia between the two groups at baseline, months 1 and 6 post surgery.", "user_data": {"pmid": "20092592"}}
{"text": "The treatment group had a statistically significant decrease in ocular surface disease index score at 6 months (P = 0.003), indicating less severity of dry eye symptoms and significant reduction in ocular pain.", "user_data": {"pmid": "20092592"}}
{"text": "Three patients in the control group were lost to follow-up.", "user_data": {"pmid": "20202537"}}
{"text": "From 533 patients randomized, 402 patients completed 24 months of therapy.", "user_data": {"pmid": "20420586"}}
{"text": "Although the IOP-lowering effect during the study was slightly larger with latanoprost, this difference was clinically small and the noninferiority of tafluprost to latanoprost over all diurnal IOP measurements was shown with anova and almost reached with ancova (upper limits of the 95% confidence intervals 1.38 and 1.52 for the overall period, respectively).", "user_data": {"pmid": "20420586"}}
{"text": "The noninferiority limit was 1.5 mmHg.", "user_data": {"pmid": "20420586"}}
{"text": "Seventy-seven eyes (77 patients) were randomized to the iridotomy group, and 81 eyes (81 patients) were randomized to the iridotomy plus iridoplasty group.", "user_data": {"pmid": "20472226"}}
{"text": "There were no significant differences between the groups in the baseline data.", "user_data": {"pmid": "20472226"}}
{"text": "Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).", "user_data": {"pmid": "20472226"}}
{"text": "There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.", "user_data": {"pmid": "20472226"}}
{"text": "IOP change at 4 weeks, % IOP reduction at 2 and 4 weeks were also significantly greater in Tafluprost than in Placebo.", "user_data": {"pmid": "20545217"}}
{"text": "Groups were well balanced regarding baseline ECD, CV and CCT (p>0.05).", "user_data": {"pmid": "20584708"}}
{"text": "CCT was significantly increased (p<0.05) at 1, 8, 15 and 30 days postoperatively, returning to baseline at 60 days in both groups.", "user_data": {"pmid": "20584708"}}
{"text": "There was no significant difference in CCT increase in both groups at any visit.", "user_data": {"pmid": "20584708"}}
{"text": "Interestingly, there were statistically significant correlations between ECD loss and phacoemulsification time (p<0.0001) and ECD loss and irrigation solution volume (p<0.0001) in the Ringer group, but not in the BSS Plus group.", "user_data": {"pmid": "20584708"}}
{"text": "The mean preoperative IOP was 24.8+/-8.9 mm Hg for all patients enrolled.", "user_data": {"pmid": "20733558"}}
{"text": "No anti-glaucomatous medication was necessary in the MMC group in the first year of follow-up, whereas five patients in the ologen group required topical treatment.", "user_data": {"pmid": "20733558"}}
{"text": "At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.", "user_data": {"pmid": "20828829"}}
{"text": "Sixty-six percent of treatment eyes versus 48% of control eyes achieved \u226520% IOP reduction without medication (P = 0.003).", "user_data": {"pmid": "20828829"}}
{"text": "The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.", "user_data": {"pmid": "20828829"}}
{"text": "Seventy-two patients were included: 34 and 38 (P\u2009=\u20090.142) with a baseline mean IOP\u2009=\u200926.52\u2009\u00b1\u20095.185 and 26.36\u2009\u00b1\u20091.605\u2009mm Hg (P\u2009=\u20090.629) for bimatoprost and travoprost, respectively.", "user_data": {"pmid": "21034177"}}
{"text": "Both drops provided statistically significant IOP reductions from baseline at all visits (P\u2009<\u20090.001).", "user_data": {"pmid": "21034177"}}
{"text": "Bimatoprost provided greater (nonsignificant) mean IOP reductions from baseline than travoprost at each visit.", "user_data": {"pmid": "21034177"}}
{"text": "Mean IOP reductions was 8.77\u2009mm Hg (33.39%) and 8.42\u2009mm Hg (31.54%) at 2 weeks (P\u2009=\u20090.703), and 8.47\u2009mm Hg (31.61%) and 7.84\u2009mm Hg (29.50%) at 6 months (P\u2009=\u20090.536) for bimatoprost and travoprost, respectively.", "user_data": {"pmid": "21034177"}}
{"text": "IOPs at 2 weeks were \u226418\u2009mm Hg in 20 (58.8%) versus 19 (50%) eyes (P\u2009=\u20090.603), and \u226416\u2009mm Hg in 12 (35%) versus 12 (32%) eyes (P\u2009=\u20090.456); and at 6 months \u226418\u2009mm Hg in 22 (65%) versus 14 (37%) eyes (P\u2009=\u20090.045), and \u226416\u2009mm Hg in 12 (35%) versus 7 (18%) eyes (P\u2009=\u20090.037) for bimatoprost and travoprost, respectively.", "user_data": {"pmid": "21034177"}}
{"text": "Ocular adverse and clinical success occurred equally with both drops.", "user_data": {"pmid": "21034177"}}
{"text": "Fifty-seven patients were randomized to undergo laser treatment and 59 were randomized to no laser (controls).", "user_data": {"pmid": "21035866"}}
{"text": "Age, gender, spherical equivalent refraction, and intraocular pressure at baseline were similar between groups.", "user_data": {"pmid": "21035866"}}
{"text": "Outcome data were available for 105 (90%) of recruited subjects, 52 in the laser treatment group and 53 in the no laser treatment group.", "user_data": {"pmid": "21035866"}}
{"text": "Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.", "user_data": {"pmid": "21035866"}}
{"text": "Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).", "user_data": {"pmid": "21035866"}}
{"text": "the age ranged between 40 to 76 years with the mean of 56.5 +/- 9.25 years.", "user_data": {"pmid": "21141017"}}
{"text": "The most common preoperative diagnosis was angle closure glaucoma.", "user_data": {"pmid": "21141017"}}
{"text": "The postoperative percentage of IOP reduction (Group A=68.9%; Group B=66.51%) was statically significant in both the groups (p=0.001).", "user_data": {"pmid": "21141017"}}
{"text": "The proportion of patients who experienced pain was significantly lower in the intracameral lidocaine group compared with the BSS group (multivariate OR 0.68, 95% CI 0.47 to 0.97; p=0.034).", "user_data": {"pmid": "21183518"}}
{"text": "Pain was more common in females (54.3% vs 43.6%; OR 1.56), non-Chinese (62.3% vs 46.9%; OR 2.13) and those who had previous cataract surgery to the fellow eye (55.3% vs 44.7%; OR 1.61).", "user_data": {"pmid": "21183518"}}
{"text": "Ninety-nine patients were randomized to brimonidine and 79 to timolol.", "user_data": {"pmid": "21257146"}}
{"text": "Mean (\u00b1 SE) months of follow-up for all patients was 30.0 \u00b1 2.", "user_data": {"pmid": "21257146"}}
{"text": "Mean treated IOP was similar for brimonidine- and timolol-treated patients at all time points.", "user_data": {"pmid": "21257146"}}
{"text": "Similar differences in progression were observed when analyzed by GCPM and the 3-omitting method.", "user_data": {"pmid": "21257146"}}
{"text": "The mean IOP was significantly lower after 1 year in both the groups (P<0.001).", "user_data": {"pmid": "21423036"}}
{"text": "Complication rates were not different between the groups.", "user_data": {"pmid": "21423036"}}
{"text": "There was no significant difference between the 2 study groups regarding the baseline characteristics and the baseline IOP (P=0.628).", "user_data": {"pmid": "21491994"}}
{"text": "Patients who received placebo as premedication had significantly higher IOP at 6 (17.96\u00b15.49 vs. 13.61\u00b14.09; P<0.001) and 12 (16.90\u00b14.11 vs. 13.96\u00b13.25; P=0.003) h postoperatively compared with those who received oral clonidine.", "user_data": {"pmid": "21491994"}}
{"text": "However, there was no significant difference between the 2 groups regarding the IOP at 24\u2009h after operation (15.41\u00b13.96 vs. 16.01\u00b13.41; P=0.0539).", "user_data": {"pmid": "21491994"}}
{"text": "The prevalence of acute IOP rise (>21 mmHg) was significantly higher in placebo group compared with clonidine group (25.8% vs. 9.6%; P=0.091).", "user_data": {"pmid": "21491994"}}
{"text": "Sixty-nine patients were treated.", "user_data": {"pmid": "21543992"}}
{"text": "Data collection terminated with 54 patients reaching 9 to 12-months follow-up.", "user_data": {"pmid": "21543992"}}
{"text": "Twenty-nine patients were in the SLT group, 25 patients in the medical group.", "user_data": {"pmid": "21543992"}}
{"text": "By last follow-up, 11% of eyes received additional SLT, 27% required additional medication.", "user_data": {"pmid": "21543992"}}
{"text": "There was not a statistically significant difference between the SLT and medication groups.", "user_data": {"pmid": "21543992"}}
{"text": "Mean overall preoperative IOP was 30.8 mmHg.", "user_data": {"pmid": "21573097"}}
{"text": "Postoperatively, mean IOPs were 11.4.3 \u00b1 4.9 and 13.6 \u00b1 3.9 mmHg, respectively for TMMC and T5-FU groups after 6 months.", "user_data": {"pmid": "21573097"}}
{"text": "In spite of some existing descriptive differences in IOP between the groups, statistical tests showed no difference in mean and median IOP.", "user_data": {"pmid": "21573097"}}
{"text": "Three cases of hypotonia (IOP < 6 mmHg) and 1 case of epithelial keratitis were detected.", "user_data": {"pmid": "21573097"}}
{"text": "Forty-one patients were recruited; 20 had standard trabeculectomy, and 21 had microtrabeculectomy.", "user_data": {"pmid": "21631670"}}
{"text": "One patient in each group required Baerveldt device implantation.", "user_data": {"pmid": "21631670"}}
{"text": "In total, 137 subjects were treated (safety population; 12-18 years, n=48; 3-<12 years, n=55; 0-<3 years, n=34).", "user_data": {"pmid": "21680022"}}
{"text": "Mean age was 8.8\u00b15.5 years, and mean baseline IOP was 27.7\u00b16.17 mmHg; 125 subjects completed the study, and 107 subjects were in the per protocol population.", "user_data": {"pmid": "21680022"}}
{"text": "Both therapies were well tolerated.", "user_data": {"pmid": "21680022"}}
{"text": "The difference in mean IOP between groups ranged from 0.2 to 0.7 \u2009mm\u2009Hg across visits and time points, with a mean pooled difference of 0.4\u2009 mm\u2009Hg (95% CI: -0.1 to 0.8), demonstrating equivalence of the two formulations.", "user_data": {"pmid": "21701528"}}
{"text": "Patients treated with fixed brimonidine-timolol adjunctive to latanoprost were significantly more likely than patients treated with adjunctive timolol to achieve an IOP <18 mmHg (P = 0.028) and a \u226520% reduction in IOP from baseline (P = 0.047) at both 8 am and 10 am in week 12.", "user_data": {"pmid": "21792284"}}
{"text": "Biomicroscopy findings were similar between the treatment groups after 12 weeks of treatment.", "user_data": {"pmid": "21792284"}}
{"text": "One-day postoperatively, the IOP dropped to 5.2 (\u00b13.5) and 9.2 (\u00b15.5) mm\u2009Hg, respectively (P=0.009).", "user_data": {"pmid": "21921953"}}
{"text": "The rates and Kaplan-Meier curves did not differ for both complete and qualified success at any target IOP.", "user_data": {"pmid": "21921953"}}
{"text": "The bleb height in OLO group was higher than MMC one (P<0.05).", "user_data": {"pmid": "21921953"}}
{"text": "SD-OCT analysis of successful/unsuccessful bleb in patients with or without complete success at IOP \u226417\u2009 mm\u2009Hg indicated a sensitivity of 83% and 73% and a specificity of 75% and 67%, respectively, for MMC and OLO groups.", "user_data": {"pmid": "21921953"}}
{"text": "No adverse reaction to OLO was noted.", "user_data": {"pmid": "21921953"}}
{"text": "A total of 643 patients were randomized and 618 completed (PF tafluprost = 306, PF timolol = 312).", "user_data": {"pmid": "22310086"}}
{"text": "At all 9 time points, the upper limits of the 2-sided 95% confidence intervals for the difference between treatments in IOP lowering were less than the prespecified noninferiority margin.", "user_data": {"pmid": "22310086"}}
{"text": "Thirty eyes of 15 patients were studied for a mean of 23.6 months (SD, \u00b1 6.9).", "user_data": {"pmid": "22344189"}}
{"text": "Complete success rates (5<IOP<18 mm Hg without medications) were higher with Ex-PRESS compared with trabeculectomy (P=0.0024).", "user_data": {"pmid": "22344189"}}
{"text": "There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline (p\u2009=\u20090.118).", "user_data": {"pmid": "22458918"}}
{"text": "Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.", "user_data": {"pmid": "22458918"}}
{"text": "The mean baseline IOP was 25.3\u00b12.8\u2009mmHg.", "user_data": {"pmid": "22775229"}}
{"text": "In addition, no difference in ocular perfusion pressure was observed between the 2 treatment groups (P=0.1, between groups).", "user_data": {"pmid": "22775229"}}
{"text": "Neither LT nor BT altered ONHBF (P=0.4, baseline vs. treatment) and no effect on flow velocities in the retrobulbar vessels was seen with either of the 2 treatments.", "user_data": {"pmid": "22775229"}}
{"text": "The incidence of adverse events was low in both groups through 24 months of follow-up.", "user_data": {"pmid": "22814041"}}
{"text": "At 24 months, the proportion of patients with an IOP of 21 mm Hg or lower without ocular hypotensive medications was significantly higher in the stent group than in the control group (P=.036).", "user_data": {"pmid": "22814041"}}
{"text": "Ocular hypotensive medication was statistically significantly lower in the stent group at 12 months; it was also lower at 24 months, although the difference was no longer statistically significant.", "user_data": {"pmid": "22814041"}}
{"text": "A total of 253 eyes of 127 subjects (mean age, 64.7 \u00b1 10.9 years; mean follow-up, 40.6 \u00b1 12 months) were analyzed.", "user_data": {"pmid": "22835512"}}
{"text": "Eyes randomized to timolol progressed faster than those randomized to brimonidine (mean rates of progression, -0.38 \u00b1 0.9 vs 0.02 \u00b1 0.7 dB/y, P < .01).", "user_data": {"pmid": "22835512"}}
{"text": "In the final multivariate model adjusting for all tested covariates, older age (hazard ratio [HR] = 1.41/decade older, 95% confidence interval [CI] = 1.05 to 1.90, P = .022), use of systemic antihypertensives (HR = 2.53, 95% CI = 1.32 to 4.87, P = .005), and mean ocular perfusion pressure (HR = 1.21/mm Hg lower, 95% CI = 1.12 to 1.31, P < .001) were associated with progression whereas randomization to brimonidine revealed a protective effect (HR = 0.26, 95% CI = 0.12 to 0.55, P < .001).", "user_data": {"pmid": "22835512"}}
{"text": "Twenty-six CACG eyes were randomized to receive phacoemulsification, and 24 eyes underwent trabeculectomy with mitomycin C. Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs. 8.9 mmHg or 36% for trabeculectomy; P=0.76).", "user_data": {"pmid": "22986111"}}
{"text": "Over first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).", "user_data": {"pmid": "22986111"}}
{"text": "However, trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs. 4%; P=0.001).", "user_data": {"pmid": "22986111"}}
{"text": "Eight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.", "user_data": {"pmid": "22986111"}}
{"text": "One hundred seventy-one patients (97.7%) attended the 3-month visit.", "user_data": {"pmid": "23059481"}}
{"text": "The IOP in the first week after trabeculectomy was significantly higher in the R group: day 1, 17.3\u00b18.6 versus 12.7\u00b16.0 mm Hg (P<0.001); day 3, 18.0\u00b17.3 versus 12.9\u00b16.3 mm Hg (P<0.001); day 7, 14.8\u00b16.3 versus 12.0\u00b14.9 mm Hg (P=0.001), but no difference was observed after the second week (P=0.659 to 0.753).", "user_data": {"pmid": "23059481"}}
{"text": "There was no difference in the occurrence of shallow chamber, choroidal detachment, macular edema, additional surgery, or hyphema (P=0.56 to 1.0).", "user_data": {"pmid": "23059481"}}
{"text": "Non-inferiority of T2345 was observed from D15.", "user_data": {"pmid": "23203707"}}
{"text": "The 95% confidence interval of the inter-group difference was greater than the pre-determined criterion of non-inferiority of brimonidine to timolol.", "user_data": {"pmid": "23285843"}}
{"text": "When added to PG analogues, the IOP-lowering effect of brimonidine (-2.9 +/- 1.8 mmHg) was greater than that of the placebo (-2.1 +/- 1.8 mmHg) (p = 0.0010).", "user_data": {"pmid": "23285843"}}
{"text": "No appreciable adverse side effects were encountered.", "user_data": {"pmid": "23285843"}}
{"text": "Eighty patients (80 eyes) were included finally: 40 eyes in each group.", "user_data": {"pmid": "23429621"}}
{"text": "Both drops provided statistically significant IOP reductions from baseline at all visits (P<0.001).", "user_data": {"pmid": "23429621"}}
{"text": "BTFC provided greater significant mean IOP reductions from baseline than TTFC at each visit (P<0.001).", "user_data": {"pmid": "23429621"}}
{"text": "IOPs at 2 weeks were \u226418 mm Hg in 36 (90.8%) versus 22 (55%) eyes and \u226416 mm Hg in 28 (70%) versus 16 (40%) eyes (P<0.001), and at 6 months, \u226418 mm Hg in 38 (95%) versus 28 (70%) eyes and \u226416 mm Hg in 30 (75%) versus 18 (45%) eyes for BTFC and TTFC, respectively (P<0.001).", "user_data": {"pmid": "23429621"}}
{"text": "The 500-mm2 implants afforded intraocular pressure control with significantly fewer medications (0.7 versus 1.3; P = 0.006).", "user_data": {"pmid": "8058290"}}
{"text": "Complication rates were statistically similar.", "user_data": {"pmid": "8058290"}}
{"text": "No upward drift in IOP occurred with either drug during the treatment period.", "user_data": {"pmid": "8628543"}}
{"text": "Latanoprost caused a somewhat more conjunctival hyperemia than timolol and more corneal punctuate epithelial erosions.", "user_data": {"pmid": "8628543"}}
{"text": "However, both drugs were generally well tolerated.", "user_data": {"pmid": "8628543"}}
{"text": "The most significant side effect of latanoprost was increased pigmentation of the iris which was observed in 15 patients (10.1%).", "user_data": {"pmid": "8628543"}}
{"text": "Timolol caused more systemic side effects than latanoprost.", "user_data": {"pmid": "8628543"}}
{"text": "Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.", "user_data": {"pmid": "8628544"}}
{"text": "Four patients treated with timolol and none treated with latanoprost were withdrawn from the study because of inadequate IOP control.", "user_data": {"pmid": "8628544"}}
{"text": "Pulse rate was significantly reduced with timolol, but not with latanoprost.", "user_data": {"pmid": "8628544"}}
{"text": "Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.", "user_data": {"pmid": "8628544"}}
{"text": "Fewer subjective side effects occurred in latanoprost-treated eyes.", "user_data": {"pmid": "8628544"}}
{"text": "Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.", "user_data": {"pmid": "8628544"}}
{"text": "Otherwise, no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.", "user_data": {"pmid": "8628544"}}
{"text": "There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P = 0.004), but not within the latanoprost group (P = 0.97).", "user_data": {"pmid": "9034838"}}
{"text": "There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P = 0.08).", "user_data": {"pmid": "9034838"}}
{"text": "No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P = 0.37).", "user_data": {"pmid": "9034838"}}
{"text": "Brimonidine lowered mean peak IOP significantly more than timolol at week 2 and month 3 (P < .03); no significant difference was observed between the groups for this variable at other visits throughout the 1-year course of the study.", "user_data": {"pmid": "9230823"}}
{"text": "No evidence of tachyphylaxis was seen in either group.", "user_data": {"pmid": "9230823"}}
{"text": "Allergy was seen in 9% of subjects treated with brimonidine.", "user_data": {"pmid": "9230823"}}
{"text": "Headache, fatigue, and drowsiness were similar in the 2 groups.", "user_data": {"pmid": "9230823"}}
{"text": "In general, the tolerance to medication was acceptable.", "user_data": {"pmid": "9230823"}}
